New drug aims to power up brain cells in Parkinson's
NCT ID NCT07322887
Summary
This study is testing whether a new oral drug called SUL-238 can improve the energy function of brain cells in people with early, untreated Parkinson's disease. Researchers will compare two doses of SUL-238 against a placebo in 45 participants over a 28-day treatment period. The main goal is to see if the drug improves specific brain energy markers measured by a specialized MRI scan, while also checking for safety and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CTC Netherlands BV
Groningen, 9713 GZ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.